quinazolines has been researched along with poziotinib in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 21 (55.26) | 24.3611 |
| 2020's | 17 (44.74) | 2.80 |
| Authors | Studies |
|---|---|
| Bang, YJ; Han, SW; Hur, HS; Im, SA; Kim, HP; Kim, MS; Kim, TY; Lee, GS; Nam, HJ; Oh, DY; Song, SH; Yoon, YK | 1 |
| Cha, MY; Chae, YJ; Kim, M; Kim, MS; Kim, YH; Lee, GS; Lee, KH; Lee, KO; Park, J; Park, SB; Song, JY; Suh, KH | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, HJ; Kim, HP; Kim, MS; Kim, TY; Lee, GS; Oh, DY; Yoon, YK | 1 |
| Hong, J; Kim, E; Kim, H; Kwon, S; Lee, G; Park, NH; Suh, K | 1 |
| Bae, KS; Jung, JA; Lim, HS; Noh, YH; Song, TH | 1 |
| Kang, MH; Kim, JH; Kim, JW; Lee, HS; Lee, JS; Lee, KW; Moon, SU; Sung, JH | 1 |
| Cho, E; Han, H; Han, JY; Jung, J; Kim, HY; Kim, SW; Lee, GK; Lee, JS; Lee, KH; Lee, SH; Lee, Y; Min, YJ; Nam, BH | 1 |
| Bang, YJ; Han, H; Han, SW; Im, SA; Kim, DW; Kim, JH; Kim, TM; Kim, TY; Kim, WH; Kim, YJ; Lee, JS; Lee, KW; Oh, DY | 1 |
| Altan, M; Brahmer, JR; Carter, BW; Chen, T; Doebele, RC; Elamin, YY; Estrada-Bernal, A; Goldberg, SB; Heymach, JV; Le, AT; Li, S; Liu, S; Lu, C; Nilsson, MB; Papadimitrakopoulou, V; Politi, K; Poteete, A; Roarty, E; Robichaux, JP; Sun, H; Tan, Z; Truini, A; Wong, KK; Zhang, S | 1 |
| Romero, D | 1 |
| Ahn, JH; Ahn, JS; Han, HS; Im, SA; Im, YH; Jung, KH; Kang, J; Kim, GM; Kim, JH; Kim, JY; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Park, IH; Park, YH; Sohn, JH | 1 |
| Choi, CM; Hur, JY; Kim, HJ; Kim, SJ; Kim, YC; Lee, JC; Lee, KY; Lee, MK; Oh, IJ; Park, CK | 1 |
| Brufsky, AM; Pandey, A | 1 |
| Chiba, M; Fujino, T; Jänne, PA; Kobayashi, Y; Koga, T; Kosaka, T; Mitsudomi, T; Nishino, M; Ohara, S; Sesumi, Y; Shimoji, M; Suda, K; Suzuki, M; Takemoto, T; Tomizawa, K | 1 |
| Im, SA; Jung, HH; Jung, KH; Kim, JH; Kim, JY; Lee, E; Lee, KH; Lee, KS; Park, K; Park, WY; Park, YH; Sohn, J | 1 |
| Bang, YJ; Cho, JY; Han, HS; Jung, SA; Kim, JS; Kim, TY; Kim, YH; Lee, KH; Lee, KW; Lee, N; Park, SH; Park, YI; Rha, SY; Song, EK; Zang, DY | 1 |
| Bai, X; Ji, Q; Ma, S; Ouyang, B; Wang, L; Yao, L | 1 |
| Aisner, J; Burley, SK; Castellano, GM; Ganesan, S; Pine, SR; Vallat, B; Yu, HA | 1 |
| Ban, S; Chen, X; Li, X; Qian, J; Yang, J | 1 |
| Ahnert, JR; Albacker, LA; Chen, T; Cross, JB; Diao, L; Elamin, YY; Frampton, GM; Han, H; He, J; Heymach, JV; Hu, L; Lanman, RB; Le, X; Li, S; Meric-Bernstam, F; Miller, VA; Negrao, MV; Nilsson, MB; Pisegna, M; Poteete, A; Raymond, VM; Robichaux, JP; Roeck, B; Routbort, M; Schrock, AB; Sun, H; Vijayan, RSK; Wang, J; Wong, KK; Yang, Z; Zhang, F | 1 |
| Hata, AN; Klempner, SJ | 1 |
| Choi, DK; Kim, JH; Kim, JW; Lee, DS; Lee, H; Min, SH; Yu, JH | 1 |
| Alamery, S; Bakheit, AH; Wani, TA; Zargar, S | 1 |
| Im, SA; Jung, KH; Kim, JH; Kim, JY; Lee, KS; Park, K; Park, YH; Sohn, J; Yang, Y | 1 |
| Kim, JW; Lee, DS; Lee, H; Min, SH | 1 |
| Kaul, SC; Kumar, V; Malik, V; Sundar, D; Wadhwa, R | 1 |
| Bottiglieri, A; Brambilla, M; de Braud, F; De Toma, A; Ferrara, R; Galli, G; Gallucci, R; Ganzinelli, M; Garassino, MC; Greco, GF; Labianca, A; Lo Russo, G; Lobefaro, R; Manglaviti, S; Nichetti, F; Occhipinti, M; Prelaj, A; Proto, C; Signorelli, D; Torri, V; Viscardi, G; Zilembo, N | 1 |
| Cardona Zorrilla, AF; Rosell, R | 1 |
| Chen, F; Dai, D; Ji, W; Meng, D; Shen, J; Wang, B; Wang, C; Wang, S; Zhou, Q; Zhou, Y | 1 |
| Fan, Y; Han, N; Lu, H; Qin, J | 1 |
| Gorski, JW; Kolesar, JM; Lin, N; Liu, J; McCorkle, JR; McDowell, AB; Riggs, MB; Ueland, FR; Wang, C | 1 |
| Ahn, BC; Cho, BC; Heo, SG; Hong, MH; Kim, HR; Lee, JH; Lim, SM | 1 |
| Altan, M; Blumenschein, G; Carter, BW; Elamin, YY; Feng, L; Fossella, FV; Gibbons, DL; Heymach, JV; Lam, VK; Le, X; Mott, FE; Negrao, MV; Patel, AB; Robichaux, JP; Tsao, AS; Zhang, J | 1 |
| Bhat, G; Clarke, JM; Cornelissen, R; Garassino, M; Goldman, JW; Heymach, JV; Le, X; Lebel, F; Leu, SY; Socinski, MA; Tchekmedyian, N | 1 |
| Guo, H; Hui, H; Shi, B; Wang, M; Wang, Y | 1 |
| Anurag, M; Chen, CH; Dobrolecki, LE; Ellis, MJ; Gutierrez, C; Kalra, R; Karanam, B; Kavuri, SM; Lewis, A; Lim, B; Salam, AB; Sallas, C; Wang, J; Yates, CC | 1 |
| Altan, M; Blumenschein, G; Byers, LA; Carter, BW; Cascone, T; Cross, JB; Elamin, YY; Feng, L; Fossella, FV; Gibbons, DL; Heeke, S; Heymach, JV; Lam, VK; Le, X; Lu, C; Luthra, R; Mantha, G; Negrao, MV; Nilsson, MB; Patel, A; Robichaux, JP; Routbort, M; San Lucas, FA; Tran, H; Tsao, AS; Vijayan, RSK; Zhang, J | 1 |
| Borm, FJ; Smit, EF | 1 |
11 trial(s) available for quinazolines and poziotinib
| Article | Year |
|---|---|
Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biotransformation; Dose-Response Relationship, Drug; Drugs, Investigational; ErbB Receptors; Female; Food-Drug Interactions; Half-Life; Humans; Hydroxylation; Intestinal Absorption; Male; Metabolic Clearance Rate; Methylation; Middle Aged; Models, Biological; Neoplasms; Quinazolines; Tablets | 2015 |
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retreatment | 2017 |
Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; ErbB Receptors; Female; Gene Amplification; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2018 |
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Recurrence; Republic of Korea; Survival Analysis | 2018 |
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positi
Topics: Adult; Algorithms; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Exons; Female; Gene Expression; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2 | 2019 |
A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prospective Studies; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Trastuzumab | 2019 |
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Topics: Ado-Trastuzumab Emtansine; Adult; Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Datasets as Topic; Disease Models, Animal; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Male; Mice; Mice, Transgenic; Mutation; Neoplasms; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2019 |
A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Class I Phosphatidylinositol 3-Kinases; Drug Administration Schedule; Drug Eruptions; Exanthema; Female; Genes, p53; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Stomatitis; Treatment Outcome; Young Adult | 2021 |
Poziotinib for Patients With
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate | 2022 |
Poziotinib in Non-Small-Cell Lung Cancer Harboring
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Prognosis; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Survival Rate | 2022 |
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2022 |
27 other study(ies) available for quinazolines and poziotinib
| Article | Year |
|---|---|
Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Synergism; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Mice; Phosphorylation; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2011 |
Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Peptide Fragments; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2012 |
Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Mitochondria; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; STAT3 Transcription Factor | 2012 |
Metabolite identification of a new tyrosine kinase inhibitor, HM781-36B, and a pharmacokinetic study by liquid chromatography/tandem mass spectrometry.
Topics: Animals; Chromatography, High Pressure Liquid; Dogs; Humans; Microsomes, Liver; Molecular Weight; Protein-Tyrosine Kinases; Quinazolines; Tandem Mass Spectrometry | 2013 |
Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; G1 Phase Cell Cycle Checkpoints; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Protein Biosynthesis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Quinazolines | 2016 |
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Topics: Afatinib; Animals; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mice; Mutagenesis, Insertional; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Tumor Burden | 2018 |
Poziotinib for uncommon ERBB mutations.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mutation; Quinazolines | 2018 |
Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Rate | 2018 |
Metastatic Breast Cancer Patient With Activating HER2 Exon 20 Insertion Mutation With Response to Poziotinib: Case Report of Compassionate Drug Use.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Exons; Female; Humans; Mutation; Phyllodes Tumor; Prognosis; Quinazolines; Receptor, ErbB-2 | 2019 |
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Exons; Humans; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2018 |
The Design, Synthesis and Preliminary Pharmacokinetic Evaluation of d3-Poziotinib Hydrochloride.
Topics: Animals; Antineoplastic Agents; Deuterium; Drug Design; Microsomes, Liver; Quinazolines; Rats | 2019 |
A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.
Topics: Acrylamides; Adenocarcinoma of Lung; Aged; Aniline Compounds; Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines; Quinolines; Tumor Stem Cell Assay | 2019 |
Successful Treatment of a Miliary Metastatic NSCLC Patient With Activating EGFR Exon 20 Insertion Mutation with Response to Poziotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Quinazolines | 2019 |
Sequence, Treat, Repeat: Addressing Resistance in EGFR-Mutant NSCLC.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mutation; Quinazolines; Quinolines | 2019 |
Poziotinib suppresses ovarian cancer stem cell growth via inhibition of HER4-mediated STAT5 pathway.
Topics: Apoptosis; beta Catenin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Down-Regulation; Female; G1 Phase; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Neoplastic Stem Cells; Ovarian Neoplasms; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-4; Receptors, Notch; Signal Transduction; Spheroids, Cellular; STAT5 Transcription Factor | 2020 |
Poziotinib and bovine serum albumin binding characterization and influence of quercetin, rutin, naringenin and sinapic acid on their binding interaction.
Topics: Antineoplastic Agents; Binding Sites; Chemistry, Pharmaceutical; Coumaric Acids; Flavanones; Flavonoids; Hydrogen Bonding; Ligands; Molecular Docking Simulation; Protein Binding; Quercetin; Quinazolines; Rutin; Serum Albumin, Bovine; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Temperature; Thermodynamics | 2020 |
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib.
Topics: Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Phosphatidylinositol 3-Kinases; Prognosis; Quinazolines; Receptor, ErbB-2; RNA, Messenger | 2020 |
Combined Poziotinib with Manidipine Treatment Suppresses Ovarian Cancer Stem-Cell Proliferation and Stemness.
Topics: AC133 Antigen; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Dihydropyridines; Female; Humans; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Nanog Homeobox Protein; Neoplastic Stem Cells; Nitrobenzenes; Ovarian Neoplasms; Piperazines; Quinazolines; STAT5 Transcription Factor; Treatment Outcome; Tumor Suppressor Proteins; Wnt Signaling Pathway | 2020 |
Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Caffeic Acids; Computational Biology; Computer Simulation; Dimerization; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Indolizines; Ligands; Lung Neoplasms; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Phenylethyl Alcohol; Quinazolines; Withanolides | 2021 |
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Compassionate Use Trials; Disease Progression; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Time Factors | 2021 |
Poziotinib treatment in intractable NSCLC: Epidermal growth factor receptor and human epidermal growth factor receptor 2 exon 20 insertion mutation disease.
Topics: Exons; Humans; Mutagenesis, Insertional; Quinazolines; Receptor, ErbB-2 | 2021 |
Effects of dacomitinib on the pharmacokinetics of poziotinib
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Chromatography, High Pressure Liquid; Drug Interactions; Humans; Inhibitory Concentration 50; Microsomes, Liver; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry | 2021 |
HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib.
Topics: Adenocarcinoma of Lung; Bevacizumab; Exons; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Mutagenesis, Insertional; Quinazolines | 2022 |
Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.
Topics: ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Neoplasm Proteins; Ovarian Neoplasms; Quinazolines | 2021 |
Poziotinib-induced cutaneous adverse reactions in the treatment of non-small cell lung cancer: A case report.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2022 |
Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2 | 2022 |
Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burden to the Therapeutic Arsenal?
Topics: Carcinoma, Non-Small-Cell Lung; Exons; Humans; Lung Neoplasms; Mutation; Quinazolines; Receptor, ErbB-2 | 2023 |